
Breast Optimization
As a concept developed by Motiva®, breast optimization creates a safer, more empowering and positive experience for women to collaborate with their surgeons to customize their desired breast appearance and feel, using a solid foundation of research and innovative, patient-centric solutions.
Established Safety & Performance
Safety and performance data collected through our robust Post-Market Surveillance System confirm that SmoothSilk®/SilkSurface® contributes to superior post-operative outcomes, with patients reporting fewer high- and low-risk complications. In particular, the data demonstrates a very low (less than 1%) capsular contracture rate in patients with SmoothSilk®/SilkSurface®.
Read more
A study performed by the Langer Lab at MIT indicated that our proprietary SmoothSilk® surface technology attracts fewer inflammatory cells than a traditional smooth surface, and it is this unique surface that is responsible for lower complication rates in breast surgery. [1]
A three-year evaluation of 5,813 patients has associated SilkSurface® implants with overall complication and revision rates of under 1 percent. That same study also reported no cases of rupture due to implant failure, capsular contracture (Baker Grades lll and IV), double capsules, or late seromas. [2]
A six-year prospective study on 35 patients reported no cases of implant rupture or malposition and no cases of capsular contracture. [3]
Bacterial biofilm accumulates on breast implant surfaces over time and has been associated with complications such as capsular contracture and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). A comparative in-vitro evaluation of SmoothSilk®, textured, and traditional smooth implants showed that bacterial attachment and biofilm formation were the lowest in SmoothSilk® implants, and highest in the textured ones. [4]
SmoothSilk®
Qid® Technology
BluSeal®
TrueMonobloc®
Ergonomics
SmoothSilk® Technology
Advanced, 360° smooth nanosurface, engineered to promote implant biointegration through:
- Lower bacteria and biofilm formation compared to macro/microtextured and traditional smooth surfaces[5],[6]
- Reduced inflammation and fibrosis formation compared to traditional smooth surfaces[7],[8]
Over more than a decade, we accumulated a body of research on breast implant surfaces and the human immune response1,3,5 demonstrating that the chronic inflammatory complications associated with macrotextured implants far outweigh any of its potential benefits.
This ultimately led us to decide never to produce aggressively textured implants, instead focusing on the development of a novel, advanced smooth surface known as SmoothSilk®/SilkSurface®, which is classified as smooth per the latest international standard (ISO-14607:2018).

Digital Passport for Instant Implant Verification
While patients may lose implant ID cards or documents, they can never lose a digital passport. As an optional feature in Motiva Implants®, Qid® is an FDA-cleared, battery-free, and passive radiofrequency identification device (RFID) microtransponder that is activated externally by a handheld reader. By storing an electronic serial number (ESN), Qid® instantly retrieves important implant information (such as manufacturing and surgery details), providing patients with invaluable peace of mind.

The First Visible Implant Barrier Layer Indicator
BluSeal®, our patented visual safety indicator, is what gives Motiva Implants® their signature light blue tint, making them the world’s only implants with a visible barrier layer that surgeons can visually verify for 100% integrity prior to insertion.

Flexible, Durable, Multilayer System
Our flexible, multilayer system known as TrueMonobloc® is designed to harmonize the shell-gel-patch interaction of Motiva Implants®, which are 100% gel-filled devices – thus reducing rippling/wrinkling while providing flexibility and durability for insertion through much smaller incisions than the standard size (as small as 2.5 cm).

The World’s First Ergonomic Implant
The predefined shape of traditional anatomical implants lack natural movement as they retain the same shape whether the patient is prone, supine, or upright.
We challenged ourselves to create an implant that looks, feels, and moves like real breast tissue.
The unique ability of Ergonomix® to mimic the natural dynamics of breast tissue (holding a teardrop shape when a patient is standing and a round shape when she is lying down) maximizes patient comfort and is particularly well suited to women with active lifestyles.

Doloff J. Overcoming host rejection response to improve breast implant biocompatibility. Oral presentation at: 3rd World Symposium on Ergonomic Implants; Sep 2017; Lago di Garda, Italy.
Sforza, Zaccheddu, et al. Preliminary 3-Year Evaluation of Experience With SilkSurface and VelvetSurface Motiva Silicone Breast Implants: A Single-Center Experience With 5813 Consecutive Breast Augmentation Cases. OUP Academic. https://academic.oup.com/asj/article/38/suppl_2/S62/4157783. Published September 14, 2017. Accessed March 30, 2020.
Quirós MC, Bolaños MC, Fassero JJ. Six-Year Prospective Outcomes of Primary Breast Augmentation With Nano Surface Implants. OUP Academic. https://academic.oup.com/asj/article/39/5/495/5181185. Published November 13, 2018. Accessed March 30, 2020.
James G, Boegli L, Hancock J et al. Bacterial Adhesion and Biofilm Formation on Textured Breast Implant Shell Materials. Aesth Plast Surg. 2019 Apr; 43:490–497.
James G, Boegli L, Hancock J et al. Bacterial Adhesion and Biofilm Formation on Textured Breast Implant Shell Materials. Aesth Plast Surg. 2019 Apr; 43:490–497.
Jones P, Mempin M, Hu H, et al. The functional influence of breast implant outer shell morphology on bacterial attachment and growth. Plast Reconstr Surg. 2018;142(4):837-849.
Doloff J. Overcoming host rejection response to improve breast implant biocompatibility. Oral presentation at: 3rd World Symposium on Ergonomic Implants; Sep 2017; Lago di Garda, Italy.
Cappellano G, Ploner C, Lobenwein S et al. Immunophenotypic characterization of human T cells after in vitro exposure to different silicone breast implant surfaces. PLoS ONE 2018;13(2):e0192108.